Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in NRAS-mutant Thyroid Cancer
NCT06970353Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in thyroid cancer, sponsored by Fudan University. Started May 2025; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06970353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970353.